Zhou ZD, Yi L, Popawska-Domaszewicz K, Chaudhuri KR, Jankovic J, Tan EK (2025) Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
A medication that acts across several of those pathways could eventually become valuable in a broader clinical context
These are typical ranges rather than guarantees
CAD Pricing: Purchasing in Canadian dollars eliminates exchange rate uncertainty and foreign transaction fees
Phillip M, Mathieu C, Lind M et al (2021) Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies
18 Other studies of high quality (randomized placebo-controlled trials) have noted benefit with these same doses with regards to measurements of Parkinsons disease severity such as the Unified Parkinsons Disease Scale Rating (UPDRS) which assess mentation, behavior, mood, activities of daily living, and motor skills among other areas impacted by Parkinsons disease
